VistaGen Therapeutics, Inc., a biotechnology company, focuses on applying proprietary human pluripotent stem cell technology for technology for drug rescue, predictive toxicology, and drug metabolism screening. The company has developed CardioSafe 3D, a novel three-dimensional in vitro bioassay system for predicting in vivo cardiac effects, both toxic and non-toxic, of small molecule drug candidates before they are tested in animals or humans. It is also developing and validating LiverSafe 3D, a novel three-dimensional in vitro bioassay system for assessing liver toxicity and drug metabolism issues. In addition, the company product candidates include AV-101, an orally available small molecule that has completed Phase 1 development for the treatment of neurological disease and disorders market, including neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
July 31, 2017
RegMed Investors’ (RMi) closing bell, another sector flip-flop
July 27, 2017
RegMed Investors’ (RMi) closing bell, the IBB dives -1.87% from yesterday’s +0.65%
July 23, 2017
RegMed Investors’ (RMi), the week’s work …
July 17, 2017
RegMed Investors’ (RMi) pre-open indications, the dangers of an alternating sector
July 14, 2017
RegMed Investors’ (RMi) closing bell, momentum with sluggish volume
July 14, 2017
RegMed Investors’ (RMi) pre-open indications, Friday seems to be a dangerous day …
July 13, 2017
RegMed Investors’ (RMi) closing bell, sector and indexes jockey for altitude
July 12, 2017
RegMed Investors’ (RMi) closing bell, a rising tide
July 11, 2017
RegMed Investors’ (RMi) closing bell, there are just too many fire drills
July 10, 2017
RegMed Investors’ (RMi) closing bell, the sector stutter steps …
35 companies, 1 interpreter!
Insight, foresight and recommendation
VistaGen (VTGN) – Started 2018 at $1.16, February saw $1.16 and March opened at $1.18 jumping to $1.47 on 3/6. Financing is always an issue yet it ended 2017 with $13 M in cash ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.